Genetic therapies are providing new hope for vaccinees as well as previously incurable diseases, but they also present new challenges for process development and control. The sheer size and complexity of products like pDNA, mRNA and AAV present a new challenge for “at-line” analytics, like distinguishing sc/oc/lin pDNA or empty from full AAV capsids.
At Sartorius BIA Separations, we are passionate about providing the best solutions for gene therapy purification, by providing a modality-specific platform for analysis and in-process control of gene therapy products.
